GENOBRO - PGS(Preimplantation Genetic Screening) Service
Negotiable Min Order Quantity Unit
- Required Quantity
-
- Place of Origin
- South Korea
- Payment Terms
- Negotiable
- Production method
- Negotiable
- Shipping / Lead Time
- Negotiable / Negotiable
- Keyword
- pgs, ngs, informatics, pre implantation genetic screening
GENOMECARE CO LTD
- Verified Certificate
-
7
Product name | GENOBRO - PGS(Preimplantation Genetic Screening) Service | Certification | - |
---|---|---|---|
Category |
Monitoring & Diagnostic Equipment
Other Monitoring & Diagnostic Equipment |
Ingredients | - |
Keyword | pgs , ngs , informatics , pre implantation genetic screening | Unit Size | - |
Brand name | - | Unit Weigh | - |
origin | South Korea | Stock | - |
Supply type | - | HS code | - |
Product Information
Pre-implantation genetic Screening
│ DESCRIPTION │
GENOBRO is pre-implantation genetic screening base on NGS(Next-Generation Sequencing), it is a fast and accurate screening in order to select genetically normal embryos. It has a much higher sensitivity and suspend time than conventional methods (FISH, aCGH) and can shorten inspection time.
Increased implantation and pregnancy success rates and elimination of embryos with chromosomal abnormalities can reduce abortion rate.
* Q. What is PGS?Pre-implantation genetic screening (PGS) for aneuploidy is a powerful genetic test that may be performed on embryo during IVF treatment to screen for numerical chromosomal abnormalities.
PGS is performed on a small embryo biopsy prior to transfer and identifies which embryos are chromosomally normal. Chromosomally normal embryos are the most likely to develop to term and to be born as a healthy baby. PGS testing helps IVF physicians and patients decide which embryos to transfer.
* Q. Who should use for PGS?• Women over 35 years of age
• Couples who have experienced several spontaneous miscarriages of unknown cause
• Couples with several cycles of IVF that have not achieved pregnancy
• Men with low sperm concentration
• Couples with a previous pregnancy with chromosomal abnormality
* Q. Key Benefit of NGS for PGS?1. Simplicity&Practical
2. Sample Throughput Flexibility and Scalability
- PGS : Once for whole sequencing - Sample -> Data Analysis
3. Best Cost-Efficiency
- NGS enables more samples per chip(at 10 samples per 316chip)
- No Need reference samples
4. New Diagnostic Possibilities
5. Rapid Turn Around Time - < 24 hours workflows
Inspection PrincipleAfter the in vitro fertilization, the embryo is harvested from 3 to 5 days after the amplification of the DNA, and then analyzed by using the next generation genome sequencing technology, which is the latest analysis technology, to analyze the chromosome abnormality more quickly and accurately. Because of this principle, the Embryos with normal chromosomes can be screened.
* Undergoing Procedure1. Collecting a part of cells Collection
2. DNA Separation and Amplification
3. Library production
4. Sequencing
5. Precise analysis
6. Check for chromosomal abnormality
* Proven normal Detection rate from Clinical TestAccording to the results of many overseas papers and clinical studies of famous international IVF centers, the proportion of normal embryos will decrease as the patient ages.
In the range of 35 to 40 years old, blastomere(3rd day of embryo) Stage is 20 to 30%, Blastocyst(5th day of Embryo) stage is 40 to 50%, those data are normal embryo detection rate and it is an international standard.
However, there are differences in the percentage of normal embryos depending on the individual characteristics of the patient and the status and stage of the embryo.
B2B Trade
Price (FOB) | Negotiable | transportation | - |
---|---|---|---|
MOQ | Negotiable | Leadtime | Negotiable |
Payment Options | Negotiable | Shipping time | Negotiable |
- President
- MyungJun Jeong
- Address
- Bdong 4F, Gwanggyuoro 145, Yeongtong-gu, Suwon-si, Gyeonggi-do, KOREA
- Product Category
- Medical Test Kit
- Year Established
- 2012
- No. of Total Employees
- 1-50
- Company introduction
-
We, Genomecare co,Ltd.,are looking for Overseas Sales Partnership as a distributor or an Exclusive Partner(Technology Transfer).
Genomcare is serving NIPT (Non-invasive prenatal Test) &PGS (Pre-implantation genetic Screening) base on NGS(Next generation Sequencing) service to our customer utilizing proton and S5XL (ThermoFisher) which are screening chromosomal abnormalities of Fetus and maternal and performed on Embryo during IVF treatment to screen for numerical chromosomal abnormalities.
We published the clinical results of NIPT in PLOS ONE&BMC Medical Genomics(Oct 2014, April 2016, Oct 2016) worldwide authoritative scientific journal. Through these experiments, Genomecare became the first sacrificially verified NIPT service provider in Korea with world-class level of NGS and data analysis competency.
ION PROTON
The Ion Proton system makes affordable, high-quality next-generation sequencing to elucidate vriants important for the heritability of cancer as well as Mendelian and complex disorders.
Exome sequecning is a targeted sequencing approach that is restricted the protein-coding region of genomes. The exome is estimated to encompass approximately 1% of the genome, yet contains approximately 85% of disease-causing mutations. For genetic researchers trying to unravel the disease-causing genes of over 6,800 rare disease, exome sequencing enables the identification of common single-nucleotide variants(SNVs) and small insertions or deletions (indels), as well as rare de novo mutations that may explain the heritabiltiy of Mendelian and complex disorders.
- Main Markets
-
Indonesia
Philippines
Singapore
South Korea
Thailand
Viet Nam
- Main Product
Related Products
Modular type ENT workstation_XU7 Basic
Best Companion
1Chip 4K, Endoscopic visual system_FX-V3
Portable, Endoscopic visual system_QVION
ICU & PATIENT Medical Solutions